Trials / Completed
CompletedNCT00496275
Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC
A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To test the safety and tolerability of ZD6474 in combination withVinorelbine (Navelbine) or Gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zactima (ZD6474) | |
| DRUG | Vinorelbine plus cisplatin | |
| DRUG | Gemcitabine plus cisplatin |
Timeline
- Start date
- 2006-08-01
- Completion
- 2007-05-01
- First posted
- 2007-07-04
- Last updated
- 2016-08-26
Source: ClinicalTrials.gov record NCT00496275. Inclusion in this directory is not an endorsement.